Medtronic receives fda expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition

Dublin, feb. 18, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced that the freezor™ and freezor™ xtra cardiac cryoablation catheters are approved by the u.s. food and drug administration (fda) and are the only ablation catheters approved to treat the growing prevalence of pediatric atrioventricular nodal reentrant tachycardia (avnrt). avnrt is the most common form of supraventricular tachycardia (svt), and is a life-threatening abnormal heart rhythm, with 89,000 cases each year and growing.
MDT Ratings Summary
MDT Quant Ranking